Biotech | September 16, 2025
Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
UTD2 is the world's first oral epothilone microtubule inhibitor
The interim data combines three mRNAs into one therapy injected directly into the tumour
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
